<DOC>
	<DOCNO>NCT00385580</DOCNO>
	<brief_summary>The purpose study learn men metastatic prostate cancer rise Prostate Specific Antigen ( PSA ) , surgically castrate undergoing androgen deprivation Luteinizing Hormone Releasing Hormone ( LHRH ) treatment , respond dasatinib . The safety treatment also study .</brief_summary>
	<brief_title>Phase II Study Dasatinib ( BMS-354825 ) Androgen-deprived Progressive Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>male , 18 old proven advance prostate cancer document metastatic disease rise PSA level castrate level testosterone symptomatic CNS ( brain spinal cord ) metastasis medical condition may increase risk toxicity prior ongoing anticancer medical therapy immunotherapy prostate cancer primary androgen deprivation agent unable take oral medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>